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Abstract
Background
The 2015WHO recommendation of antiretroviral therapy (ART) for all immediately following
HIV diagnosis is partially based on the anticipated impact on HIV incidence in the surround-
ing population. We investigated this approach in a cluster-randomised trial in a high HIV
prevalence setting in rural KwaZulu-Natal. We present findings from the first phase of the
trial and report on uptake of home-based HIV testing, linkage to care, uptake of ART, and
community attitudes about ART.
Methods and Findings
Between 9 March 2012 and 22 May 2014, five clusters in the intervention arm (immediate
ART offered to all HIV-positive adults) and five clusters in the control arm (ART offered
according to national guidelines, i.e., CD4 count 350 cells/μl) contributed to the first
phase of the trial. Households were visited every 6 mo. Following informed consent and
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administration of a study questionnaire, each resident adult (16 y) was asked for a finger-
prick blood sample, which was used to estimate HIV prevalence, and offered a rapid HIV
test using a serial HIV testing algorithm. All HIV-positive adults were referred to the trial
clinic in their cluster. Those not linked to care 3 mo after identification were contacted by a
linkage-to-care team. Study procedures were not blinded.
In all, 12,894 adults were registered as eligible for participation (5,790 in intervention
arm; 7,104 in control arm), of whom 9,927 (77.0%) were contacted at least once during
household visits. HIV status was ever ascertained for a total of 8,233/9,927 (82.9%), includ-
ing 2,569 ascertained as HIV-positive (942 tested HIV-positive and 1,627 reported a known
HIV-positive status). Of the 1,177 HIV-positive individuals not previously in care and fol-
lowed for at least 6 mo in the trial, 559 (47.5%) visited their cluster trial clinic within 6 mo. In
the intervention arm, 89% (194/218) initiated ART within 3 mo of their first clinic visit. In the
control arm, 42.3% (83/196) had a CD4 count 350 cells/μl at first visit, of whom 92.8% ini-
tiated ART within 3 mo. Regarding attitudes about ART, 93% (8,802/9,460) of participants
agreed with the statement that they would want to start ART as soon as possible if HIV-posi-
tive. Estimated baseline HIV prevalence was 30.5% (2,028/6,656) (95% CI 25.0%, 37.0%).
HIV prevalence, uptake of home-based HIV testing, linkage to care within 6 mo, and initia-
tion of ART within 3 mo in those with CD4 count 350 cells/μl did not differ significantly
between the intervention and control clusters. Selection bias related to noncontact could
not be entirely excluded.
Conclusions
Home-based HIV testing was well received in this rural population, although men were less
easily contactable at home; immediate ART was acceptable, with good viral suppression
and retention. However, only about half of HIV-positive people accessed care within 6 mo of
being identified, with nearly two-thirds accessing care by 12 mo. The observed delay in link-
age to care would limit the individual and public health ART benefits of universal testing and
treatment in this population.
Trial registration
ClinicalTrials.gov NCT01509508
Author Summary
WhyWas This Study Done?
• A study in stable sexual partners in which one partner was HIV-positive and the other
partner was HIV-negative (and both partners had disclosed to each other) showed that
if the HIV-positive partner was on antiretroviral therapy, there was a 96% reduction in
HIV transmission from the HIV-positive partner to the HIV-negative partner.
• However, we do not know if antiretroviral therapy prescribed to HIV-positive individu-
als in the general population—and where individuals might not disclose their HIV status
to sexual partners—would have a similar impact on HIV transmission.
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• It is important to determine whether prescribing antiretroviral therapy to all HIV-posi-
tive individuals is more effective at decreasing HIV transmission than starting individu-
als on antiretroviral therapy only once their HIV has progressed to the point at which
local HIV treatment guidelines currently recommend that HIV-positive individuals start
treatment.
What Did the Researchers Do and Find?
• We designed an experiment to investigate whether antiretroviral therapy can reduce
new HIV infections in the general population, and piloted the trial in ten communities
in KwaZulu-Natal, South Africa, to check whether starting HIV-positive individuals on
antiretroviral therapy directly after diagnosis is feasible and acceptable.
• We visited people in their homes, offered HIV rapid tests every six months to all individ-
uals 16 years and older, and referred identified HIV-positive individuals to trial clinics,
where they were offered antiretroviral therapy either regardless of their CD4 count
(intervention group) or when they were treatment-eligible per current national guide-
lines (control group).
• During the two-year study, we contacted 9,927 (77%) of 12,894 eligible individuals and
ascertained the HIV status of 80% of contacted women and 75% of contacted men.
• HIV-positive status was ascertained for 1,339 adults who were not previously in care;
1,177 were followed in the trial at least 6 mo after referral, of whom 559 (47.5%) engaged
with care within this period.
What Do These Findings Mean?
• Our findings show good acceptance of home-based HIV testing in rural South Africa
but highlight the challenges in reaching adequate numbers of people to offer HIV tests
to, especially among men.
• We also found that linkage to care was slower than expected, but amongst those who
reached the clinics, uptake of antiretroviral therapy was high, with the majority of indi-
viduals achieving good control of the virus.
• Our study informs health care professionals, planners, and policy makers about the chal-
lenges that need to be addressed to achieve the UNAIDS target of 90% of people living
with HIV aware of their HIV diagnosis, 90% on antiretroviral therapy, and 90% achiev-
ing good control of the virus, with testing and treatment offered to all.
Introduction
Although significant gains have been made in the control of the HIV epidemic in many sub-
Saharan countries, the annual number of new HIV infections remains unacceptably high [1].
Approximately 6.3 million people were estimated to be living with HIV in South Africa alone
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in 2013, of whom 3.1 million were on antiretroviral therapy (ART) [2]. Adult HIV prevalence
in KwaZulu-Natal province in 2011 was estimated to be as high as 30% in peri-urban commu-
nities [3], making this province an ideal setting to evaluate the impact of universal test and
treat on HIV incidence.
HIV viral load (VL) in HIV-positive individuals is the dominant determinant of transmis-
sion [4]. Effective ART lowers VL and thus substantially decreases the risk of HIV transmis-
sion. In heterosexual couples in stable relationships, ART provided to the HIV-positive partner
with T cell lymphocyte CD4+ count between 250 and 550 cells/μl reduced transmission to the
HIV-negative partner by 96% [5]. Repeat annual population-based HIV surveys in rural Kwa-
Zulu-Natal, South Africa, have shown that individual-level HIV acquisition risk decreased by
38% when ART coverage in the surrounding community increased from<10% to 30%–40%
under national treatment guidelines (first ART initiation at a CD4 count of200 cells/μl, then
at350 cells/μl) [3]. The impact on HIV transmission at the population level of ART initiation
in all HIV-positive individuals soon after HIV diagnosis has not yet been evaluated in a trial
setting.
Mathematical models have suggested that significant reductions in HIV transmission could
be achieved with optimisation of every step of the HIV care cascade—starting with high uptake
of regular HIV testing in all adults—and with immediate treatment initiation in those found to
be HIV-positive [6]. The Joint United Nations Programme on HIV/AIDS (UNAIDS) has set
targets that by 2020, 90% of all people living with HIV will know their HIV status, 90% of all
people with diagnosed HIV infection will receive sustained ART, and 90% of all people receiv-
ing ART will achieve viral suppression (the 90-90-90 targets) [7]. However, the impact of the
HIV care cascade on HIV incidence would additionally depend on the context of the sexual
networks (such as heterogeneity, concurrency, and mixing) in which HIV transmission occurs
[8–10].
Experience from public health HIV treatment programmes highlights the challenges of
reaching high uptake of HIV testing, linkage to care, ART initiation, and long-term treatment
adherence [11]. A recent meta-analysis of 28 studies that evaluated several approaches to com-
munity-based HIV testing including door-to-door HIV testing amongst 555,267 participants
reported an HIV test acceptance rate of 80% (95% CI 76.9%, 83.1%), with higher HIV test
acceptance in community-based than in facility-based programmes, although the former iden-
tified fewer HIV-positive people and with substantially less advanced disease [12]. There are
limited data on repeat HIV testing, but one population-based study in rural Malawi reported
repeat HIV testing uptake of 96% amongst participants who tested HIV-negative in a previous
survey and were recontacted [13]. Linkage to care and ART initiation present further chal-
lenges in the HIV care cascade, with results from a further meta-analysis of sub-Saharan Afri-
can data showing that for every 100 patients with a positive HIV test, 72 had a CD4 count
performed, 40 were deemed ART-eligible by national treatment criteria, and only 25 started
ART [14]. However, somewhat more positively, a recent evaluation of self-testing for HIV and
linkage to care in Blantyre, Malawi, reported that 56% of individuals who tested HIV-positive
linked to care within 12 mo [15]. There are little, if any, data on the acceptability and uptake of
immediate ART for HIV prevention in African populations [16,17].
In early 2012, we initiated a cluster-randomised trial in rural KwaZulu-Natal to evaluate
whether immediate ART in HIV-positive individuals could significantly reduce HIV incidence
at the population level. At the time of implementation, similar trials were still in their planning
phase [18,19]; with the complexity of implementing such a large trial and a lack of available
data to inform the design and sample size, we opted to start the interventions in a limited num-
ber of clusters randomised for the main trial. We were able to evaluate process indicators such
as uptake of initial and repeat home-based HIV testing, linkage to care, uptake of ART, and
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community attitudes and beliefs about HIV, which are important for the success of the main
trial as well as for HIV treatment programmes more generally.
Methods
Ethics Statement
The trial was approved by the Biomedical Research Ethics Committee (BFC 104/11) at the Uni-
versity of KwaZulu-Natal and the Medicines Control Council of South Africa. (ClinicalTrials.
gov: NCT01509508; South African National Clinical Trials Register: DOH-27-0512-3974). All
participants provided written or witnessed thumbprint informed consent.
Study Design
ANRS 12249 TasP is a cluster-randomised trial including 22 clusters (2 × 11) at full implemen-
tation. The full trial protocol has been published previously [20]. The protocol underwent
some modification in response to changes in South African national ART guidelines and to
optimise trial implementation procedures by introducing an active linkage-to-care team in
both arms in May 2013 to facilitate linkage to trial clinics for those not linked to care within 3
mo of being referred. These amendments were approved by the Biomedical Research Ethics
Committee of the University of KwaZulu-Natal and the trial data and safety monitoring board.
We here present results on process indicators from the first phase of the trial in ten (2 × 5)
clusters; four (2 × 2) of the ten clusters began enrolment on 9 March 2012, and the remaining
six (2 × 3) on 22 January 2013. A total of three HIV survey rounds were conducted in the initial
four clusters between 9 March 2012 and 31 August 2013, and two in the remaining six clusters
between 22 January 2013 and 5 April 2014. Follow-up for all those identified as HIV-positive
and receiving care in trial clinics started on 9 March 2012, depending on cluster implementa-
tion date, and ended on 22 May 2014.
Trial Setting
This cluster-randomised trial was implemented in the Hlabisa sub-district of the uMkhanya-
kude district in northern KwaZulu-Natal, South Africa. The area is largely rural, with scattered
homesteads and a national road on the boundary, adjacent to the Africa Centre for Population
Health and its demographic surveillance area. It is served by the Hlabisa Department of Health
HIV treatment and care programme [21].
Study Procedures
The study procedures and instruments have been fully described previously [20,22]. Proce-
dures relevant to the first phase of the trial are summarised below.
Home-based procedures. In each home-based HIV testing and survey round, conducted
every 6 mo, homestead (a bounded physical structure usually comprising one household but
occasionally two or more households with different household heads) visits took place between
8:00 A.M. and 4:30 P.M. weekly from Tuesday to Saturday. Where required, separate homestead
visits took place between 10:00 A.M. and 6:30 P.M. from Thursday to Sunday to accommodate
adults not contacted during the standard homestead visit times, mainly students and employed
individuals.
Individuals were eligible for trial participation if they were aged16 y and resident (defined
as spending four or more nights per week) members of a household in the designated cluster.
Individuals were ineligible if they did not fulfil the criteria for residency or lacked the mental
capacity to give informed consent.
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Verbal consent from the homestead owner was obtained before entering any homestead.
After explaining the study, each household head was asked to enumerate all eligible household
members and complete a household asset form. Eligible individuals present on the day were
taken to a private area and consented in writing to respond to a social and sexual behaviour
questionnaire and give a finger-prick blood sample, collected on filter paper as dried blood
spots (DBSs). An individual was considered a trial participant if they agreed to complete a
study questionnaire, although opting out of providing DBSs was accepted. DBS samples col-
lected longitudinally during survey rounds were tested using HIV ELISA in the Africa Centre
for Population Health laboratory in Durban for identification of new cases of HIV infection,
which is the primary outcome of the main trial. Researchers and study participants were
blinded to these longitudinal DBS results.
HIV pretest counselling and a finger-prick rapid HIV test were offered, following a separate
written consenting process, to individuals who completed the study questionnaire, using a
serial HIV testing algorithm [23]. HIV 1/2 Gold Screening Test (G-Ocean, Hong Kong, China)
was used as the first test, for screening, and Alere Determine HIV-1/2 (Alere, Kempton Park,
South Africa) was used as the second test, for confirmation of HIV-positive results, in line with
the provincial Department of Health (DoH) protocol. This protocol was later amended on 20
September 2012 to Alere Determine HIV-1/2 for screening and First Response HIV-1/HIV-2
test kit (Premier Medical Corporation, Kachigam, India) for confirmation, following changes
in the DoH directive.
The result of the rapid HIV test was given to each participant, with counselling as appropri-
ate, and further psychological support was offered for any serious distress observed. Those who
newly tested HIV-positive or who self-reported being HIV-positive were referred to the TasP
trial clinic in their cluster. Those who self-reported being HIV-negative were documented as
having refused to be tested.
Procedures offered to eligible individuals were the same in each repeat survey round, irre-
spective of their HIV status recorded in the previous round.
TasP trial clinic procedures. HIV-positive participants attending TasP trial clinics were
asked to provide written consent to (i) complete clinical history and examination question-
naires and provide blood specimens for VL testing and (ii) receive care as per national guide-
lines and ART as per cluster allocation. HIV-positive participants comprised those newly
diagnosed as HIV-positive and those who self-reported as HIV-positive during home-based
survey visits; they could be either ART-naïve or ART-experienced from their previous HIV
care provider.
All consenting HIV-positive participants underwent clinical evaluation and a point-of-care
CD4 measurement (Alere Pima CD4 test, Alere, Waltham, MA, US). All participants eligible
for ART attended adherence and ART literacy sessions and initiated ART within 2 wk of the
baseline visit, or sooner if severely immunocompromised. A fixed dose combination of tenofo-
vir/emtricitabine/efavirenz (Atripla) was used for first-line ART, except if a participant’s clini-
cal condition indicated otherwise. Second-line ART was informed by the results of genotypic
resistance tests in participants failing first-line ART.
Participants receiving ART underwent monthly clinical evaluation including scheduled
safety monitoring blood and HIV VL measurements (Abbott m2000 RealTime System, Abbott
Molecular, Des Plaines, IL, US) at the first visit, at 3 and 6 mo after ART initiation, and every 6
mo thereafter. They were also interviewed for clinical adverse events. Unscheduled clinic visits
were also allowed for participants with clinical complaints. In the control clusters, patients not
yet eligible for ART were invited to return to the study clinic in 4 to 6 mo for pre-ART care,
positive prevention services, repeat clinical assessment, and CD4 count measurement. Partici-
pants missing a trial clinic appointment were phoned, and, when possible, a new appointment
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was scheduled. Participants who failed to link to care 3 mo after being referred by the field
team were contacted by a trial linkage-to-care team either by phone or through a home visit.
Intervention
In the intervention clusters, HIV-positive individuals were informed during home-based HIV
testing that they would be provided ART irrespective of CD4 count and clinical stage. In the
control clusters, HIV-positive individuals were informed that ART would be offered according
to the criteria of the national South African guidelines: CD4 count 350 cells/μl, World Health
Organization (WHO) clinical stage 3 or 4, or coinfection with multidrug resistant or exten-
sively drug-resistant tuberculosis.
Definition of Variables and Outcomes
S1 Table presents the outcomes measured in phase 1 and presented here, and those that will be
measured after trial completion.
HIV prevalence was estimated on the basis of antibody test results from the DBSs collected
during the first survey round only. We estimated ART coverage at the start of the trial (propor-
tion of all HIV-positive individuals on ART) among those with positive DBS results (first sur-
vey round) using linked information from DoH clinics and pharmacy records (ARTemis and
iDART databases). Matching between the three databases was based on first names, last name,
date of birth, South African ID number, and cell phone numbers.
Means and medians (interquartile ranges [IQRs]) for age at registration and other demo-
graphic characteristics were computed among individuals who completed at least one individ-
ual questionnaire at home.
Proportion of individuals contacted and whose HIV status was ascertained was computed
per home-based survey round, i.e., an individual eligible in three survey rounds (taking into
account round of registration and population exits), fully contacted in two rounds, but accept-
ing an HIV rapid test only in one round will contribute three episodes in the denominator and
two episodes in the numerator for estimation of contact, and two episodes in the denominator
and one in the numerator for HIV ascertainment. The HIV status of an individual was ascer-
tained if that person accepted an HIV rapid test and obtained a valid result (i.e., invalid/inde-
terminate results excluded) or if he/she self-reported being HIV-positive.
Rapid HIV test uptake was computed amongst individuals who were contacted, did not self-
report being HIV-positive, and accepted a rapid HIV test.
Linkage to care within 6 mo was computed among individuals who were ascertained as
HIV-positive at home, not previously in care (in DoH clinics in the study area), and observed
at least 6 mo (taking into account population exits and the end date of data collection). Linkage
to care was defined as having a first clinic visit either in a DoH clinic in the study area or a
TasP clinic and was obtained by individual linkage in the databases as described above.
ART uptake within 3 mo of the first clinic visit was computed in TasP clinics only, among
participants not on ART at the first clinic visit, regardless of ART eligibility criteria. ART
uptake was further stratified by CD4 count at first visit in the TasP clinics.
Viral suppression was defined as having VL< 400 copies/ml on ART.
We estimated the status within the HIV care cascade (diagnosed, ever on ART, ever virally
suppressed during the trial follow-up) of trial participants who were contacted and identified
to be HIV-positive (through DBS results and/or HIV rapid test) who linked to TasP or DoH
clinics, using linked information from DoH clinics. In order to present a population cascade,
we also estimated the number of HIV-infected individuals who had not been reached by the
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trial field activities by applying the observed HIV prevalence (from DBS results) to the total
population of registered individuals. This assumes there was no selection bias.
Attitude indicators were computed (i) among individuals who completed at least one indi-
vidual questionnaire at home (the first questionnaire was used for individuals who completed
several questionnaires over the trial) or (ii) among HIV-positive participants who linked to
TasP clinics, at their first visit, if they were not already on ART at this first clinic visit.
Sample Size
The main trial at full implementation was 80% powered to detect an overall 34% reduction in
cumulative HIV incidence over 4 y (n = 22,000; 22 clusters), with an incidence of 2.25% per
year in the control clusters. The calculation made allowance for 20% loss to follow-up and
assumed a coefficient of variation of 0.25 to account for variation between clusters [20].
Assumptions for attaining this incidence reduction were that the level of population contact
would need to be 90%, HIV status ascertainment 80%, linkage to care 70%, and baseline HIV
prevalence 24%.
Randomisation
Randomisation was performed by the trial statisticians before the start of the trial. 211 local
areas were aggregated into 48 clusters. Initial sample size calculation showed that 34 clusters
(2 × 17) would be required, and these were randomly allocated to the two arms, control and
intervention. Randomisation was carried out within each stratum to derive an equal number of
control and intervention communities per stratum. Random number generation and the ran-
domisation procedure were performed in MapInfo version 11.0. The sample size was subse-
quently amended to 2 × 11 with an increase in the duration of follow-up through a revision of
the protocol for the main trial. For this initial phase, only ten (2 × 5) of the 22 clusters were
used. To minimise the degree of between-cluster variation, clusters were stratified on the basis
of predicted HIV prevalence, extrapolating from HIV surveillance data from the Africa Centre
for Population Health’s demographic surveillance area and data from antenatal clinics (six
strata).
Statistical Analyses
Process indicators were summarised by arm and described according to key baseline character-
istics (sex, age, education level, marital status, and professional status). They were then com-
pared by arm using Pearson’s chi² test with Rao-Scott second-order correction, which is
appropriate in the context of cluster sampling [24]. The p-values were computed with a Sat-
terthwaite approximation to the distribution and with denominator degrees of freedom as rec-
ommended by Thomas and Rao [25] or with a design-based t-test (taking into account
clustering for variance computation).
Results
Registration and Enrolment of Participants
Three consecutive rounds of home-based HIV testing were conducted in four initial clusters
(2 × 2) starting 9 March 2012, and two rounds in six additional clusters (2x3) starting 22 Janu-
ary 2013. A total of 12,894 individuals were registered as eligible between 9 March 2012 and 22
May 2014 (Fig 1). During this period, 9,927 (77.0%) were contacted by the fieldworkers at least
once, with no difference between arms (77.7% in the intervention arm and 76.4% in the control
arm). Of the 9,927 individuals ever contacted, 9,490 (95.6%) agreed to complete a social and
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sexual behaviour questionnaire at least once, and HIV status was ascertained at least once for
82.3% (3,698/4,496) and 83.5% (4,535/5,431) in the intervention and control arms, respectively
(Fig 1); this translates to ascertained HIV status for 63.9% (3,698/5,790) and 63.8% (4,535/
7,104) of all registered individuals, respectively.
Overall, the HIV prevalence was 30.5% (95% CI 25.0%, 37.0%).
Baseline Characteristics
The median age (IQR) of participants was 32.3 y (22.1–52.4), and the majority were female
(67.9%). A third of participants had primary education or less. The majority were never mar-
ried; very few were formally employed. No difference was observed between arms (Table 1).
Fig 1. Flow diagram of enrolment by trial arm and sex in the ANRS 12249 TasP trial.
doi:10.1371/journal.pmed.1002107.g001
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Contact and Uptake of HIV Testing per Round
The proportion of registered individuals contacted per survey round was 66.8%, similar in both
arms (p = 0.530) but lower in males than females (53.3% versus 75.2%). Uptake of rapid HIV
test at first contact was 73.1% overall, similar in both arms (Table 2). Amongst those contacted,
HIV status ascertainment (rapid HIV test uptake plus self-reported HIV-positive) per survey
round was 77.6%, also similar between arms (p = 0.676) (Table 2).
Repeat HIV test uptake was 85.3% at second contact in those testing HIV-negative at first
contact. Cumulatively in all survey rounds, 2,569 adults were ascertained as HIV-positive (942
tested HIV-positive and 1,627 reported a known HIV-positive status) and referred to TasP
clinics in their cluster (Fig 1).
Amongst the 1,694 individuals who were contacted at least once but whose HIV status was
never ascertained, 573 (33.8%) did not provide any reason for refusal. Amongst the remaining
1,121 individuals, 545 (48.6%) ever reported that they thought they were HIV-negative, 353
(31.5%) were afraid to test, 96 (8.6%) would test only with their partner, and 323 (28.8%) pro-
vided other reasons (overall proportion differs from 100% due to multiple reasons per
individual).
Linkage to Care
Of the 2,569 adults ascertained as HIV-positive and referred to TasP clinics, 1,230 were actively
engaged with care in DoH clinics at the time of referral (Fig 1). Amongst the remaining 1,339
adults, 1,177 were followed in the trial at least 6 mo after referral (Table 2). Of these, 559
(47.5%) linked to care within 6 mo of referral, with no significant difference between arms
(p = 0.970). The corresponding estimate at 12 mo was 63.1% (376/596) overall, again not sig-
nificantly different between arms (p = 0.912).
Uptake of ART and Retention
In the intervention arm, among participants not already on ART who were followed at least 3
mo in TasP clinics, 103/118 (87.3%) participants with CD4 count> 350 cells/μl initiated ART
within 3 mo of the first clinic visit (Table 2). There was no difference between arms in the
Table 1. Baseline characteristics of participants in intervention and control arms, first phase of the TasP ANRS 12249 trial, 2012–2014.
Characteristic Intervention Arm Control Arm p-Value
Number of registered individuals 5,790 7,104
Estimated baseline HIV prevalence (n/N) 29.0% (880/3,036) 31.7% (1,148/3,620) 0.672
Estimated baseline ART coverage (n/N) 36.0% (317/880) 39.8% (457/1,148) 0.271
Number of participants who completed at least one questionnaire 4,244 5,246
Female 68.4% 67.4% 0.486
Mean age (years) at registration 39.0 38.1 0.944
Median age (IQR) 33.3 (22.4–53.3) 31.6 (21.9–51.8)
Never been married 67.0% 69.1% 0.678
Primary education or less 42.6% 39.7% 0.133
Employed 9.4% 9.9% 0.842
Condom use at last sexual act (IQ1) 29.3% 32.2% 0.342
p-Values correspond to Pearson’s chi² tests with Rao-Scott second-order correction or design-based t-tests (taking into account clustering) for a difference
between the intervention and control arms.
IQ1, ﬁrst administered questionnaire at home.
doi:10.1371/journal.pmed.1002107.t001
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proportion of treated individuals who achieved viral suppression (448/526, 85.2%, in the inter-
vention arm and 440/518, 84.9%, in the control arm). The median (IQR) duration on ART was
265 d (162–383).
Retention in care in trial clinics at 12 mo was 84.4%, slightly higher in the intervention than
in the control arm (86.2% versus 82.5%).
HIV Care Cascade
Among an estimated total of 3,933 (30.5% HIV prevalence × 12,894) HIV-infected individuals
16 y living within the trial area, 2,706 (68.8%) were diagnosed (2,569 ever ascertained within
TasP plus 137 not ascertained within TasP but ever in care in a DoH clinic), of whom 1,898
Table 2. Process indicators by trial arm and by sex, first phase of the ANRS 12249 TasP trial, 2012–2014.
Process Indicator Women Men Overall Difference in Proportions
for Women versus Men
Percent (95% CI) p-Value
Intervention arm, percent (n/N)
Contact per home-based survey round 74.4% (5,554/7,465) 50.3% (2,305/4,587) 65.2% (7,859/12,052) 24.1 (21.4, 26.9) <0.001
HIV ascertainment per home-based survey round 76.8% (4,264/5,554) 76.6% (1,765/2,305) 76.7% (6,029/7,858) 0.2 (−4.1, 4.5) 0.932
Linkage to care within 3 mo (individuals not in care at referral) 36.7% (159/433) 38.1% (67/176) 37.1% (226/609) −1.3 (−9.7, 7.0) 0.770
Linkage to care within 6 mo (individuals not in care at referral) 47.4% (188/397) 48.2% (79/164) 47.6% (267/561) −0.8 (−5.0, 3.3) 0.724
Linkage to care within 12 mo (individuals not in care at
referral)
62.6% (134/214) 62.6% (57/91) 62.6% (191/305) 0.0 (−3.4, 3.4) 0.991
ART initiation within 3 mo of ﬁrst clinic visit (CD4 count  350
cells/μl at baseline)
95.0% (57/60) 85.0% (34/40) 91.0% (91/100) 10.0 (−2.9, 22.9) 0.073
ART initiation within 3 mo of ﬁrst clinic visit (CD4 count > 350
cells/μl at baseline)
89.8% (79/88) 80.0% (24/30) 87.3% (103/118) 9.8 (−3.5, 23.1) 0.168
Control arm, percent (n/N)
Contact per home-based survey round 75.8% (6,426/8,475) 56.0% (2,904/5,189) 68.3% (9,330/13,664) 19.8 (16.6, 23.1) <0.001
HIV ascertainment per home-based survey round 80.4% (5,165/6,426) 73.9% (2,146/2,904) 78.4% (7,311/9,326) 6.5 (3.9, 9.0) 0.009
Linkage to care within 3 mo (individuals not in care at referral) 35.6% (190/534) 39.3% (72/183) 36.5% (262/717) −3.4 (−7.8, 0.3) 0.137
Linkage to care within 6 mo (individuals not in care at referral) 47.3% (218/461) 47.7% (74/155) 47.4% (292/616) −0.4 (−4.5, 3.6) 0.838
Linkage to care within 12 mo (individuals not in care at
referral)
62.9% (146/232) 66.1% (39/59) 63.6% (185/291) −3.2 (−17.9, 11.5) 0.700
ART initiation within 3 mo of ﬁrst clinic visit (CD4 count  350
cells/μl at baseline)
93.3% (56/60) 91.3% (21/23) 92.8% (77/83) 2.0 (−6.3, 10.3) 0.587
ART initiation within 3 mo of ﬁrst clinic visit (CD4 count > 350
cells/μl at baseline)
9.8% (9/92) 14.3% (3/21) 10.6% (12/113) −4.5 (−21.4, 12.4) 0.565
Difference in proportions for intervention versus control arm, percent (95% CI), p-value
Contact per home-based survey round −1.4 (−9.1, 6.3), 0.730 −5.7 (−17.1, 5.6), 0.353 −3.1 (−12.1, 6.0), 0.530
HIV ascertainment per home-based survey round −3.6 (−11.7, 4.5), 0.386 2.7 (−5.0, 10.4), 0.525 −1.6 (−9.3, 6.0), 0.676
Linkage to care within 3 mo (individuals not in care at referral) 1.1 (−11.8, 14.1), 0.866 −1.3 (−9.4, 6.9), 0.525 0.6 (−10.4, 11.6), 0.921
Linkage to care within 6 mo (individuals not in care at referral) 0.1 (−10.4, 10.5), 0.990 0.4 (−8.7, 9.6), 0.929 0.2 (−9.5, 9.9), 0.970
Linkage to care within 12 mo (individuals not in care at
referral)
0.3 (−16.6, 16.0), 0.971 −3.5 (−25.5, 18.6), 0.766 −1.0 (−17.4, 15.5), 0.912
ART initiation within 3 mo of ﬁrst clinic visit (CD4 count  350
cells/μl at baseline)
1.7 (−3.9, 7.2), 0.571 −6.3 (−24.5, 11.9), 0.518 −1.8 (−11.2, 7.7), 0.719
ART initiation within 3 mo of ﬁrst clinic visit (CD4 count > 350
cells/μl at baseline)
80.0 (73.2, 86.8), <0.001 65.7 (43.2, 88.2), 0.003 76.7 (68.4, 85.0), <0.001
p-Values correspond to Pearson’s chi² tests with Rao-Scott second-order correction (taking into account clustering) for a difference between women and
men or between the intervention and control arms. Proportion of individuals contacted and whose HIV status was ascertained was computed per home-
based survey round, i.e., an individual eligible in three survey rounds, fully contacted in two rounds, but accepting a HIV rapid test only in one round will
contribute three episodes in the denominator and two episodes in the numerator for estimation of contact, and two episodes in the denominator and one in
the numerator for HIV ascertainment.
doi:10.1371/journal.pmed.1002107.t002
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(70.1%) were ever in care in a TasP and/or DoH clinic, of whom 1,343 (70.8%) achieved viral
suppression (Fig 2). Overall, 34.1% (1,343/3,933) of all HIV-positive individuals were ever
virally suppressed.
Attitude Indicators and Other Observations
Almost all participants in both arms were of the opinion that people should test regularly and
agreed that they would start ART as soon as possible if diagnosed HIV-positive, with no differ-
ence by arm (Table 3).
One female participant newly identified as HIV-positive among the 6,155 individuals who
underwent 10,445 HIV rapid tests in the home suffered an acute adjustment reaction with
Fig 2. Estimated HIV care cascade among all HIV-infected individuals at the population level. *The number of non-observed
HIV-positive individuals was estimated under the assumption that there was no selection bias, i.e., the observed HIV prevalence of
30.5% was applied to individuals whose HIV status was not observed within TasP. The 2,983 amongst the HIV-infected individuals in
column 1 refers to the total number of individuals ascertained as HIV-positive within TasP in both arms of the trial, 2,569 (Fig 1), plus
those who declined HIV rapid test but whose DBS HIV ELISA was positive and matched that of 137 individuals on ART within the DoH
clinics.
doi:10.1371/journal.pmed.1002107.g002
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suicidal intent; she was referred to a clinical psychologist for support and care. There were
no reports of study-related gender-based violence, partnership dissolution, or breach of
confidentiality.
Discussion
This 2-y initial phase of a trial evaluating a treatment as prevention strategy in a rural South
African setting confirmed programmatic challenges in reaching optimum numbers of individ-
uals for HIV testing at home during working hours, especially men, hindering HIV status
ascertainment. However, among those contacted, uptake of initial and repeat HIV testing was
high. Linkage to care in adults newly diagnosed with HIV was slower than expected, but of
those who reached the trial clinic, uptake of ART was high regardless of CD4 count, with good
viral suppression and retention. These observations are particularly relevant given the most
recent WHO guidelines recommending ART be initiated in anyone diagnosed with HIV, irre-
spective of CD4 cell count [26]. We show a drop-off at each of the first two steps of the HIV
care cascade, which would undermine the effectiveness of such a universal testing and treat-
ment policy in reducing HIV transmission.
We were unable to contact one-quarter of the potential target population, especially men;
however, home-based HIV testing was effective in ascertaining the HIV status of those con-
tacted. Our results are in line with those from a meta-analysis including 28 studies that showed
a pooled 80% uptake of home-based HIV testing [12]. Individuals unaware of their HIV-posi-
tive status cannot benefit from ART for their own health, and as they would remain potential
transmitters, the population as a whole would not benefit either. Mobile HIV testing has
recently been shown to be more efficient than home-based approaches in increasing contact
and testing uptake in men [27–29] and in younger individuals and should be considered as a
complementary approach in settings such as ours. Concerns about stigma and breach of confi-
dentiality are often cited as reasons for HIV test refusal, but actual harm is rarely reported in
published studies [12]. We identified only one serious adverse event following nearly 11,000
home-based tests, which highlights the quality of the pre- and post-test counselling.
First-time clinic engagement was limited, with only 47.5% of HIV-positive participants not
already in care attending a trial or DoH clinic within 6 mo of referral, with 63% linkage at 12
mo. Our findings are in line with the findings from a study in Malawi of HIV self-testing and
Table 3. Attitudes towards repeat home-based HIV testing and early treatment by trial arm, first phase of the ANRS 12249 TasP trial, 2012–2014.
Attitude Indicator Percent (n/N) p-Value
Intervention Arm Control Arm
Consider that people should test regularly (IQ1) 93.3% (3,961/4,244) 92.9% (4,876/5,246) 0.846
Consider that best place to get HIV tested is “at home” (IQ1) 60.4% (2,564/4,244) 56.5% (2,965/5,246) 0.505
Agree that would want to start ART as soon as possible if
HIV-positive (IQ1)
93.1% (3,951/4,244) 92.5% (4,851/5,246) 0.688
Believe that antiretroviral drugs make people with HIV less
infectious (IQ1)
78.7% (3,340/4,244) 75.3% (3,948/5,246) 0.472
Less worried about HIV now that treatments have improved
(IQ1)
81.9% (3,476/4,244) 84.2% (4,419/5,246) 0.258
Agree that ART will reduce transmission to sexual partners
(HIV+ patients, ﬁrst visit in TasP clinic, not already on ART)
77.1% (219/284) 82.9% (252/304) 0.601
p-Values correspond to Pearson’s chi² tests with Rao-Scott second-order correction (taking into account clustering) for a difference between the intervention
and control arms.
IQ1, ﬁrst administered questionnaire at home.
doi:10.1371/journal.pmed.1002107.t003
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linkage to care [15] as well as those from a systematic review and meta-analysis of 11 sub-Saha-
ran African studies, which reported that only 57% of those diagnosed HIV-positive had been
linked to care [30]. The delay in accessing the trial clinics in our study may be associated with
earlier HIV identification, in individuals who were asymptomatic, in home-based testing. Fur-
thermore, our study did not show much difference in delay in accessing care between those in
the intervention arm (who were told that ART would be provided to all) and those in the con-
trol arm (who were told that ART would be provided to those who were treatment-eligible).
However, there were some anecdotal reports that fear of stigma may have discouraged rapid
linkage to care, as trial clinics provided services only to HIV-positive individuals; ongoing
social science work embedded within the trial may shed more light on this issue [22]. Further,
about one-fifth of HIV-positive individuals who entered into care reported being unaware of
the link between VL and HIV transmission; this highlights the need to incorporate this infor-
mation into ART literacy and adherence counselling sessions.
The observed uptake of ART once linked to care was high both in treatment-eligible and
not-yet-eligible individuals, with 85% of those initiating ART achieving viral suppression
(VL< 400 copies/ml) in both arms. Retention was equally high in the two arms in the first
year following treatment initiation. In contrast, in a study in urban Soweto, one in five HIV-
positive individuals eligible for ART refused to initiate ART [31]. In that study, “feeling
healthy” was the commonest reason given for ART refusal, despite a median CD4 count of 110
cells/μl and high rates of tuberculosis. In a qualitative study in Kenya to explore HIV serodis-
cordant couples’ attitudes toward early initiation of ART, most participants reported interest
in initiating ART early, citing individual health benefits and preventing HIV transmission as
motivators [16]; with side effects, lifelong adherence, and stigma emerging as potential
barriers.
Overall, we estimated that only one-third of all individuals living with HIV in this popula-
tion were on ART and virally suppressed. However, we were able to link data from DoH clinics
only for the trial participants who were contacted and observed HIV-positive (through DBS
results and/or ascertainment). We do not have this information for nearly one-quarter of indi-
viduals not reached by the trial or who refused to participate, who may be in HIV care at DoH
clinics. Hence, the overall proportion of HIV-positive individuals in the population with viral
suppression should be considered an underestimate, while the value of 45.0% (1,343/2,983)
with viral suppression computed only among observed HIV-positive individuals constitutes an
upper estimate. There remains an important gap in reaching the UNAIDS target of 73% (90%
of 90% of 90%) of all people living with HIV being virally suppressed.
The 2013WHO guidelines for ART recommended initiation at CD4 count 500 cells/μl
and immediate ART initiation among specific groups including serodiscordant couples. Follow-
ing two large randomised clinical trials [32,33] reporting health benefits in individuals initiating
ART at higher CD4 counts, the WHO recently concluded that universal testing and treatment
should become the standard of care [26]. Many African countries, including South Africa since
January 2015, had already adopted the 2013 guidelines. Trials, including ours, currently under-
way in South Africa, Zambia, Botswana, Uganda, and Kenya that were originally designed to
show a decrease in HIV incidence with ART initiated at a CD4 count of350 cells/μl in the
control arm have had to adapt to these expanding treatment eligibility criteria [18,19]. It is likely
that when the 2015WHOHIV treatment guidelines are adopted and implemented in these
countries, the research focus in these trials may shift to evaluations of programmes that aim to
achieve theWHO/UNAIDS 90-90-90 targets (90% of people living with HIV aware of their
HIV status, 90% of people diagnosed HIV-positive on ART, 90% of people on ART virally sup-
pressed) by 2020 [7], which our study shows could potentially be challenging. As these changes
have not yet been implemented in South Africa, they do not affect the analysis in this paper.
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Study limitations include the use of a subset of the original randomisation for the initial
phase of the trial, comprising fewer clusters, but this did not seem to affect the distribution of
baseline characteristics between the two arms. Although household contact rates were high, we
were unable to contact all individuals identified as eligible for the trial, in particular men. Non-
contact could potentially be a source of bias, if different between arms. These limitations high-
light the challenges of a universal test and treat policy.
In summary, we show that home-based HIV testing was well received in this population,
although men were less easily contactable during the day of home visits, and that immediate
ART was acceptable, with good viral suppression and retention. However, only about half of
the HIV-positive people identified accessed care within 6 mo, with nearly two-thirds by 12 mo;
the improvement with time would suggest that people take time in accessing care, rather than
refuse to link to care altogether.
These findings inform the now topical debate of how to identify HIV-positive people in the
community and to improve the rate of linkage to care, and provide important input in further
statistical projections about the burden of HIV and treatment need for populations with high
HIV prevalence, such as in sub-Saharan Africa.
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